Pyxis Oncology, Inc.

REDWOOD CITY, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced the appointment of Jakob Dupont, M.D., to its Board of Directors. Dr. Dupont brings more than two decades of experience in the field of oncology and immuno-oncology. With the appointment of Dr. Dupont, Executive Partner at Sofinnova Investments, Dr. Jim Healy, M.D., Ph.D., also at Sofinnova, will be stepping down as Lead Independent Director. In addition, Frank D. Lee will be departing the Board and Brian O’Callaghan, CEO of Deep Genomics, will be assuming the role of Chair. “Jakob has deep experience in successfully developing therapies that help cancer patients, and we are honored to have him join our Board of Directors. Jakob’s proven track record and knowledge in drug development will be beneficial as we continue to advance our pipeline and support our collaborations,” said Willie Quinn, Chief Executive Officer. “Jim and Frank have provided excellent counsel to Bolt and on behalf of the whole Board of Directors, I would like to thank them for their insights and dedication. I am also excited that Brian is stepping forward to be Chair of the board, and we all look forward to his leadership.” Dr. Dupont is Executive Partner, Private Equity at Sofinnova Investments. Prior to joining Sofinnova, Dr. Dupont was Global Head of Research & Development and Executive Vice President at Atara Biotherapeutics, where he led the development and regulatory approval of EBVallo ® . He also served as Chief Medical Officer at Gossamer Bio. Before Gossamer Bio, Dr. Dupont served as Vice President and Global Head of Breast and Gynecologic Cancer Development for Genentech/Roche, where he was responsible for the global development of Herceptin ® , Perjeta ® , Kadcyla ® , and Tecentriq ® , among others, and where he previously led the development of Avastin ® for Gynecologic and Breast Cancers when starting his industry career. He serves as a Board Member for Avenzo Therapeutics, Pyxis Oncology, and Imugene, and is on the Scientific Advisory Board for Flagship Pioneering. Dr. Dupont earned his bachelor’s degree from Vassar College, his master’s degree from New York University, and his M.D. from the Joan & Sanford I. Weill Medical College of Cornell University. “I’m pleased to join the Bolt Biotherapeutics Board of Directors,” said Jakob Dupont, M.D., Executive Partner, Private Equity, Sofinnova Investments. “The recent strategic restructuring has left Bolt in an enviable position of having an ongoing clinical trial with a first-in-class Dectin-2 agonist and a near-clinical ISAC program targeting Claudin 18.2. Additionally, Bolt has the resources, in the form of cash, platform technology, and a solid team, to pursue its mission of harnessing the power of the immune system to improve lives and eradicate cancer. I look forward to sharing my experience with the Bolt team as they advance their pipeline programs through clinical development.” About Bolt Biotherapeutics, Inc. Bolt Biotherapeutics is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. Bolt Biotherapeutics’ pipeline candidates are built on the Company’s deep expertise in myeloid biology and cancer drug development. The Company’s pipeline includes BDC-3042, a first-in-class agonist antibody that activates macrophages by targeting Dectin-2, and BDC-4182, a next-generation Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) clinical candidate targeting claudin 18.2. BDC-3042 is currently in a Phase 1 dose escalation trial that includes patients with any of seven different solid tumor types. BDC-4182 is supported by strong in vitro and in vivo data demonstrating potent anti-tumor activity, and activities are underway to support the initiation of clinical trials in 2025. Bolt Biotherapeutics is also developing additional Boltbody™ ISACs in strategic collaborations with leading biopharmaceutical companies. For more information, please visit . Forward-Looking Statements This press release contains forward-looking statements about us and our industry that involve substantial risks and uncertainties and are based on our beliefs and assumptions and on information currently available to us. All statements other than statements of historical facts contained in this press release, including statements regarding the advancement and success of our BDC-3042 clinical trial, the potential initiation of clinical trials for BDC-4182, the anti-tumor potency, safety and tolerability, and characteristics of our product candidates, the initiation of future clinical trials, the potential value of collaborations, and the expected duration of our cash runway, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “on track,” “plan,” “potential,” “predict,” “project,” “should,” “will,” or “would,” or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements represent our current beliefs, estimates and assumptions only as of the date of this press release and information contained in this press release should not be relied upon as representing our estimates as of any subsequent date. These statements, and related risks, uncertainties, factors and assumptions, include, but are not limited to: the potential product candidates that we develop may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release; such product candidates may not be beneficial to patients or become commercialized; and our ability to maintain our current collaborations and establish further collaborations. These risks are not exhaustive. Except as required by law, we assume no obligation to update these forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future. Further information on factors that could cause actual results to differ materially from the results anticipated by our forward-looking statements is included in the reports we have filed or will the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2023. These filings, when available, are available on the investor relations section of our website at investors.boltbio.com and on the SEC’s website at . Investor Relations and Media Contact: Matthew DeYoung Argot Partners (212) 600-1902 boltbio@argotpartners.com

BOSTON, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced that Lara S. Sullivan, M.D., President and Chief Executive Officer, will participate in fireside chats and members of management will participate in one-on-one meetings at the following two upcoming investor conferences: Morgan Stanley 22nd Annual Global Healthcare Conference in New York, NY, on September 6 at 12:20 PM Eastern Time H.C. Wainwright 26th Annual Global Investment Conference in New York, NY, on September 9 at 2:00 PM Eastern Ti A live webcast and replay of the presentations will be available on the Events & Presentations page in the Investor Relations section of Pyxis Oncology’s website, ir.pyxisoncology.com. About Pyxis Oncology, Inc. Pyxis Oncology, Inc. is a clinical stage company focused on defeating difficult-to-treat cancers. The company is efficiently building next generation therapeutics that hold the potential for mono and combination therapies. PYX-201, an antibody-drug conjugate (ADC) that uniquely targets EDB+FN within the tumor stroma, and PYX-106, a fully human Siglec-15-targeting antibody designed to block suppression of T-cell proliferation and function, are being evaluated in ongoing Phase 1 clinical studies in multiple types of solid tumors. Pyxis Oncology’s therapeutic candidates are designed to directly kill tumor cells and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. Pyxis Oncology’s ADC and immuno-oncology (IO) programs employ novel and emerging strategies to target a broad range of solid tumors resistant to current standards of care. To learn more, visit www.pyxisoncology.com or follow us on Twitter and LinkedIn. Forward Looking StatementsThis press release contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. These statements are often identified by the use of words such as “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “intend,” “likely,” “may,” “might,” “objective,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “to be,” “will,” “would,” or the negative or plural of these words, or similar expressions or variations, although not all forward-looking statements contain these words. We cannot assure you that the events and circumstances reflected in the forward-looking statements will be achieved or occur and actual results could differ materially from those expressed or implied by these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those identified herein, and those discussed in the section titled “Risk Factors” set forth in Part II, Item 1A. of the Company’s Quarterly Report on Form 10-Q filed with SEC on August 14, 2024, and our other filings, each of which is on file with the Securities and Exchange Commission. These risks are not exhaustive. New risk factors emerge from time to time, and it is not possible for our management to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date hereof and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely upon these statements. Except as required by law, we undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date of such statements. Pyxis Oncology Contact Pamela Connealy CFO and COO ir@pyxisoncology.com

None Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry. Please send the good word—or the bad—from your shop to Darren Incorvaia or Gabrielle Masson and it will be featured here at the end of each week. BioMarin builds up with biotech leadersBioMarin Pharmaceutical Coastal California biotech BioMarin Pharmaceutical is bringing two biotech vets on board to lead its new-look R&D and deals teams. The two people joining the company are Greg Friberg, M.D., and James Sabry, M.D., Ph.D. Friberg, who spent 18 years at Amgen, will take the title of chief research and development officer, replacing the retiring Hank Fuchs, M.D. Sabry, who left Roche in May after 14 years, is set to join as chief business officer. StoryMoonwalk lands VP, new advisory boardMoonwalk BiosciencesJohn Liles, Ph.D., is joining the leadership team of epigenetic and AI focused Moonwalk as vice president of biology and translational science. Liles previously served more than a decade each in leadership roles at Chinook Therapeutics—which was acquired by Novartis in 2023—and Gilead Sciences. Moonwalk has also assembled a new cardiometabolic advisory board made up of five experts. ReleaseGenmab adds new roles to executive team as COO splitsGenmabDanish antibody specialist Genmab created two new positions on its executive team as its chief operating officer Anthony Mancini jumps ship to pursue “other opportunities.” Amgen vet Rayne Waller will take on the new role of chief technology officer, while Genmab’s Brad Bailey was promoted into the new chief commercial officer slot after serving as the company’s U.S. general manager since that role’s inception in 2020. Story> Paul Streck, M.D., who has previously held CMO roles at several different companies, will join PepGen as its new head of R&D. Release> Genetic medicine maker SalioGen Therapeutics tapped Kalliopi Stasi, M.D., Ph.D., as CMO. Release> Tiziana Life Sciences has a new CEO in Ivor Elrifi, a decorated intellectual property and patent attorney. Release> Dimitrios Arkilo, M.D., is joining the team at Actio Biosciences as CMO. Release> Francis Sarena, who helped lead Apexigen’s acquisition by Pyxis Oncology, is the new chief operating officer at 89bio. Release> Immunotherapy-focused Cidara Therapeutics is bringing Jim Beitel on board as chief business officer, replacing Preetam Shah, Ph.D., who will continue as chief financial officer. Release> Pierre Gagnon is resigning as chief operating officer of NKGen Biotech. Filing> Coya Therapeutics is promoting chief business officer Arun Swaminathan, Ph.D., to CEO effective Nov. 1, replacing Howard Berman, Ph.D., who will continue on as executive chair. Release